Fight-or-flight response triggers white bloods cells, increases heart attack risk in diabetics
Stress hormones can save lives, or take them. Released during an emergency or in pressure situations, stress hormones can gang up with white blood cells to fight infections or lead to heart attacks.
New research from the University of Pittsburgh School of Medicine, published today in the journal Immunity, shows that white bloods cells, which typically heal infections and injuries, can become overactive and cause inflammation in plaques in blood vessels, making them vulnerable to rupture and hemorrhage in people with diabetes.
"If the rupture occurs in the coronary artery, the person has a heart attack. If the rupture occurs in the carotid artery, it causes a stroke," said Partha Dutta, D.V.M., Ph.D., assistant professor of medicine at Pitt's School of Medicine.
The major cause of death in people with diabetes is heart attack, and nearly one-third of the U.S. population has diabetes or prediabetes.
Studying patients and mice with diabetes, Dutta and his team found that when the fight-or-flight response is triggered, it also triggers the over-production of fighting white blood cells, or leukocytes. They also showed for the first time that stress hormones, called catecholamines, are produced in the spleen by a sub-group of white blood cells. Previous studies have shown that they were produced only by the sympathetic nervous system.
In the spleen, stress hormones trigger the proliferation of granulocyte macrophage progenitor cells, which in turn create inflammatory myeloid cells. Large amounts of inflammatory myeloid cells, which are linked to heart attack, were found in plaque in blood vessels. Further, the granulocyte macrophage progenitor cells expressed high levels of beta 2 receptors for stress hormones. Interestingly, patients who were taking beta 2 blockers were found to have fewer inflammatory cells.
"The findings suggest that diabetic patients could be treated with beta 2 blockers to reduce the number of inflammatory myeloid cells that cause plaque to rupture," said Dutta, the senior author of the study. "If patients are on beta 2 blockers, the spleen will still be making the myeloid cells necessary to fight infection, but in smaller amounts.
Although decreasing white blood cells may be a problem for people with diabetes who are prone to infection, we need to weigh the cost of preventing infections and preventing death.
Additional authors on this research are Sathish Babu Vasamsetti, Ph.D., Jonathan Florentin, Ph.D., Emilie Coppin, Ph.D., Muhammad Umer Nisar, M.D., John Sembrat, David Levinthal, M.D., Ph.D., Mauricio Rojas, M.D., Kang Kim, Ph.D., all from Pitt; Lotte Stiekema, Ph.D., Erik S. Stroes, M.D., and Kang H. Zheng, Ph.D., of University of Amsterdam, The Netherlands.
National Institutes of Health (NIH) grants 4R00HL121076-03 and 1R01HL143967 supported this research. NIH grant 1S10RR027383-01 supported the small animal imaging system, and NIH grant 1S10OD019973-01 supported the confocal microscope.
About the University of Pittsburgh Schools of the Health Sciences
The University of Pittsburgh Schools of the Health Sciences include the schools of Medicine, Nursing, Dental Medicine, Pharmacy, Health and Rehabilitation Sciences and the Graduate School of Public Health. The schools serve as the academic partner to the UPMC (University of Pittsburgh Medical Center). Together, their combined mission is to train tomorrow's health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease and participate in the delivery of outstanding patient care. Since 1998, Pitt and its affiliated university faculty have ranked among the top 10 educational institutions in grant support from the National Institutes of Health. For additional information about the Schools of the Health Sciences, please visit http://www.health.pitt.edu.